Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Pulmonary artery banding using polytetrafluoroethylene; Choice of material20220410595ENMohammad Hassan NezafatiAssociate Professor, Department of Cardiovascular Surgery, Mashhad University of Medical Sciences, Mashhad, IranPouya NezafatiGeneral Practitioner, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0003-2551-8335Mehdi KahramAssistant Professor, Department of Cardiovascular Surgery, Mashhad University of Medical Sciences, Mashhad, Iran0000-0002-8914-5702Journal Article20170709This article does not have an abstract Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Gensini scores and well-being states among patients with coronary artery disease: A comparison study20521010596ENReza RostamiAssociate Professor, Department of Psychology and Education, School of Psychology and Education Science, University of Tehran, Tehran, IranMahdi NajafiAssociate Professor, Tehran Heart Center AND Department of Anesthesiology, School of Medicine, Tehran University of Medical Sciences AND Cardiac Outcome Research and Education (CORE), Universal Scientific Education and Research Network (USERN), Tehran, IranReza SaramiAssistant Professor,, Department of Psychology, School of Psychology, Kharazmi University, Tehran, IranAli BozorgiAssistant Professor, Department of Cardiology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranMajid SoltaniGeneral Practitioner, Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, IranPayman SalamatiProfessor, Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran,Journal Article20160511BACKGROUND: World Health Organization (WHO) considered Mental Health Continuum (MHC) as a good instrument for well-being studies. Moreover, gensini score (GS) is an intensity index for coronary artery disease (CAD). The aim of our study was to compare GSs among patients who had coronary artery disease with different well-being states. METHODS: This was a cross-sectional study conducted in Tehran Heart Center, Iran, in 2013. The study population consisted of 50 non-depressed patients who were candidates for coronary artery bypass graft (CABG). All of the participants were interviewed according to the Iranian version of Mental Health Continuum (IV-MHC) and were allocated to flourishing, maternal mental health (MMH) and languishing states based on the related classification criteria. GS was calculated for each participant. Data were analyzed by SPSS. RESULTS: Forty one (82%) patients were in flourishing, 9 (18%) in MMH and nobody was in languishing states. The mean (standard deviation) of GS was 90.43 (44.424) and 89.67 (33.378) for flourishing and MMH ones, respectively (P = 0.962). There was no statistically significant correlation between GSs and well-being states (all Ps > 0.050). CONCLUSION: Considering IV-MHC classification, all of our patients were only allocated to flourishing and MMH states. There was no relationship between intensity of CAD and the states (P > 0.050). We recommend further research with larger sample sizes for better evaluation of the Iranian version of the instrument. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Design and implementation of a combined observational and interventional study: Trends of prevalence, awareness, treatment and control hypertension and the effect of expanded chronic care model on control, treatment and self-care21122010597ENMaryam Eghbali-BabadiPhD Candidate, Hypertension Research Center, Cardiovascular Research Institute AND School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, IranAlireza KhosraviAssociate Professor, Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000.0003.0736.2090Awat FeiziAssociate Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute AND Department of Biostatistics and Epidemiology, Isfahan University of Medical Sciences, Isfahan, IranNizal SarrafzadeganProfessor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranJournal Article20170408BACKGROUND: Lack of information about hypertension leads to failure in detection, treatment and reduced estimation of this disease effects. So, a comprehensive study, named trends of prevalence, awareness, treatment and control hypertension among the adults in Isfahan, Iran (2001-2016) and evaluation of the effect of expanded chronic care model (ECCM) on control, treatment and self-care, has been designed. This study explains the aspects of design and methods of its implementation. METHODS: This study was conducted in four stages in 2014-2016. In the 1st­ stage, valid questionnaires were made to assess knowledge, attitude and practice, and self-care. In the 2nd stage, the status of prevalence, awareness, treatment and control and hypertension risk factors was assessed. In the 3rd­ stage, a two-group clinical trial was conducted to evaluate the effectiveness of ECCM on hypertensive patients and their families. In the 4th­ stage, the results of hypertension prevalence and its risk factors in adults in 2016 were compared with two other studies undertaken in 2001 and 2007. RESULTS: To develop the questionnaire, face and content validity, internal and external reliability, and construct validity were examined. Prevalence, awareness, treatment and control of hypertension and risk factors among 2107 adult individuals were determined in Isfahan. In a clinical trial, 216 hypertensive patients were randomly assigned into intervention and control groups. Finally, a sample size of 8073 people was used to determine and compare the 15-year-old trend of hypertension and its affecting factors. CONCLUSION: It is obvious that the final findings of this study will play a key role in health and research policy and provide a suitable model for implementing appropriate interventional measures at the provincial and national levels. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts22122910598ENMohammad Hashemi-JaziProfessor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranSayed Mojtaba HosseiniProfessor, Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranAli GholamrezaeiGeneral Practitioner, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranJournal Article20150416BACKGROUND: We investigated clinical and procedural factors associated with the no-reflow phenomenon following percutaneous coronary intervention (PCI) of the saphenous-vein grafts (SVG). METHODS: A cross-sectional study was done on patients who had undergone PCI of the SVG. Patients’ medical documents were reviewed for demographic, clinical, laboratory, and procedural data. Slow/no-reflow was defined based on the thrombolysis in myocardial infarction (TIMI) grade (0 to 2). Univariate and multiple logistic regression analyses were performed to investigate factors associated with slow/no-reflow and P < 0.050 was considered as significant. RESULTS: A total of 205 patients were studied (81% man, mean ± standard deviation of age was 66.8 ± 9.6 years). Slow/no-reflow was found in 38 (18.5%) patients. High diastolic blood pressure (P = 0.010), leukocytosis (P = 0.017), diffuse lesions (P = 0.007), degenerated SVG (P < 0.001), proximal lesions (P < 0.001), thrombosis (P = 0.013), and lower number of used stents during procedure (P = 0.032) were associated with slow/no-reflow in unadjusted analyses. Factors independently associated with slow/no-reflow were pre-procedural high diastolic blood pressure with odds ratio (OR) = 3.858 [95% confidence interval (95% CI), 1.157-12.860], degenerated SVG with OR = 5.901 (95% CI: 1.883-18.492), proximal lesions with OR = 5.070 (95% CI: 1.822-14.113), pre-intervention TIMI grade with OR = 0.618 (95% CI: 0.405-0.942), number of used stents for PCI with OR = 0.074 (95% CI: 0.011-0.481) for > 1 stent, and length of stents used for PCI with OR = 0.100 (95% CI: 0.019-0.529) for > 30 mm stents. CONCLUSION: This study on the clinical and procedural factors associated with the slow/no-reflow phenomenon following PCI of the SVG can be used in risk estimation of this serious complication and tailoring preventive strategies to at-risk patients. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Allopurinol prophylactic therapy and the prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography: A prospective randomized controlled trial23023510599ENLeili IraniradAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, IranMohammad Saleh SadeghiStudent Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, IranAhmadreza BagheriAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, IranKobra DoostaliAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, IranSamieh NorouziAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, IranSeyed Fakhreddin HejaziAssistant Professor, Department of Cardiology, School of Medicine, Qom University of Medical Sciences, Qom, IranHossein SaghafiAssociate Professor, Department of Internal Medicine, School of Medicine, Qom University of Medical Sciences, Qom, IranSakineh Roshani-MobarakiNursing Research Center AND School of Medicine, Qom University of Medical Sciences, Qom, IranJournal Article20160627BACKGROUND: Contrast-induced nephropathy (CIN) is considered to be a possibly severe complication of radiography and thus, remains to be the main cause of acute kidney injury (AKI) for inpatients. A clinical trial was executed to measure the preventive effect of allopurinol against CIN in high-risk patients undertaking coronary angiography. METHODS: Through randomized controlled trial, 140 patients with at minimum two risk factors of CIN, undertaking coronary angiography, were randomly allocated to the allopurinol (n = 70) or control group (n = 70). Those in the allopurinol group received allopurinol (300 mg) a day before their coronary angiography and intravenous hydration for 12 hours before and after their procedure, while members of the control group only received intravenous hydration. Serum creatinine (SCr), blood urea nitrogen (BUN) and uric acid were measured before and 48 hours after the procedure. CIN was defined by a 25% increase in SCr or the concentration of > 0.5 mg/dl, 48 hours after coronary angiography. RESULTS: CIN was observed in 8 (11.4%) patients in the allopurinol group and 11 (15.7%) patients in the control group. There was no significant difference in the incidence of CIN between the two groups at 48 hours after coronary angiography (P = 0.459). In the allopurinol group, the median SCr concentration decreased non-significantly from 1.16 mg/dl to 1.13 mg/dl, 48 hours after coronary angiography (P = 0.189). In the control group, the median SCr concentration increased significantly from 1.11 mg/dl to 1.2 mg/dl, 48 hours after coronary angiography (P < 0.001). CONCLUSION: Allopurinol presents no considerable effectiveness over the hydration protocol for development of CIN in high-risk patients. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171111Persian Registry Of cardioVascular diseasE (PROVE): Design and methodology23624410600ENMahshid GiviHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-8766-2151Nizal SarrafzadeganIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-8352-0540Mohammad GarakyaraghiHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-6298-9905Ghasem YadegarfarHeart Failure Research Center, Cardiovascular Research Institute AND Department of Epidemiology and Biostatic, School of Public Health, Isfahan University of Medical Sciences, Isfahan, IranMasoumeh SadeghiCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-7179-5558Alireza KhosraviHypertension Research Center AND Cardiac Intervention Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0003-0736-2090Amir Hossein AzhariHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-3249-7491Mohammad Reza SamienasabIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranDavood ShafieHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-7999-2393Mohammad SaadatniaIsfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-9425-5132Hamidreza RoohafzaIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences ,Isfahan, Iran0000-0003-3582-0431Navid PaydariIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences ,Isfahan, IranAzam SoleimaniCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0003-2529-5223Mohsen HosseinzadehPediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranSeyed Abdullah AhmadiIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranLeila DehghaniSchool of Advanced Technologies in Medicine, ShahidBeheshti University of Medical Sciences, Tehran, IranJamshid NajafianIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0002-1472-1218Elham AndalibIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranJavad ShahabiHeart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-6902-2150Mohammad Reza SabriPediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran0000-0001-9726-6144Journal Article20170612BACKGROUND: Our aim was to create and establish a database called “Persian Registry Of cardioVascular diseasE (PROVE)” in order to be used for future research and in addition, as a tool to develop national guidelines for diagnosis, treatment, and prevention of cardiovascular disease (CVD). In this paper, the design and methodology of the PROVE pilot study will be discussed, launched in Isfahan, Iran, in 2015-2016. METHODS: Through establishing PROVE, patients' data were collected from hospitals and outpatient clinics prospectively or retrospectively and followed up for a maximum of three years based on the type of CVDs. The inclusion criteria were as patients with acute coronary syndrome (ACS), ST elevation myocardial infarction (STEMI), stroke, atrial fibrillation (AF), heart failure (HF), congenital heart disease (CHD), percutaneous coronary intervention (PCI), and chronic ischemic cardiovascular disease (CICD). Specific protocols, questionnaires, and glossaries were developed for each registry. In order to ensure the validation of the protocols, questionnaires, data collection, management, and analysis, a well-established quality control (QC) protocol was developed and implemented. Data confidentiality was considered. RESULTS: In order to register patients with ACS, STEMI, stroke, HF, PCI, and CICD, the hospital recorded data were used, whereas, in case of AF and CHD registries, the data were collected from hospitals and outpatient clinics. During the pilot phase of the study in Isfahan, from March 2015 to September 2016, 9427 patients were registered as ACS including 809 as STEMI, 1195 patients with HF, 363 with AF, 761 with stroke, 1136 with CHD, 1200 with PCI, and 9 with CICD. Data collection and management were performed under the supervision of the QC group. CONCLUSION: PROVE was developed and implemented in Isfahan as a pilot study, in order to be implemented at national level in future. It provides a valuable source of valid data that could be used for future research, re-evaluation of current CVD management and more specifically, gap analysis and as a tool for assessment of the type of CVDs, prevention, treatment, and control by health care decision makers. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: A double blind randomized clinical trial24525210601ENAli JavandoostMetabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAsma AfshariAssistant Professor, Department of Nutrition, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranIrandokht Nikbakht-JamMetabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranMohammad KhademiPhD Candidate, Student Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranSaied EslamiProfessor, Pharmaceutical Research Center AND School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranMina NosratiBiochemistry and Nutrition Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranMojtaba Foroutan-TanhaMetabolic Syndrome Research Center AND Cardiovascular Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAmirhossein SahebkarAssociate Professor, Department of Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranShima TavalaieBiochemistry and Nutrition Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranMajid Ghayour-MobarhanProfessor, Cardiovascular Research Center AND Metabolic Syndrome Research Center AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran0000-0002-1081-6754Gordon FernsSchool of Brighton and Sussex Medical, Division of Medical Education, Mayfield House, University of Brighton, Brighton, UKFarzin HadizadehProfessor, Biotechnology Research Center AND School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, IranAbolghasem TabassiPharmacological Research Center of Medicinal Plants AND School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranAhmad MohajeriAssociate Professor, Pharmacological Research Center of Medicinal Plants, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranJournal Article20160119BACKGROUND: Metabolic syndrome is defined by insulin resistance and a clustering of other cardiovascular risk factors. Crocin is a carotenoid derived from the stigmas of the saffron flower and had previously been shown to affect lipid profile. However, the mechanism for this function is not well understood. The present trial aimed to investigate the possible effect of crocin on plasma levels of cholesteryl ester transfer protein and lipid profile in individuals with metabolic syndrome. METHODS: This was a randomized, double-blind, placebo-controlled, clinical trial consisting of an 8-week treatment with crocin, or placebo tablets between April and June 2014, in the Nutrition Clinic of Ghaem Teaching Hospital, Mashhad, Iran. Participants were randomly assigned to take a 30 mg/day crocin (n = 22) in the intervention group or placebo (n = 22) in the control group. Anthropometric, hematological and biochemical parameters were measured and recorded during pre and post-treatment periods. RESULTS: Whilst plasma cholesteryl ester transfer protein was increased in the group taking the crocin tablet by 27.81% during the trial period (P = 0.013), the difference between the crocin and placebo groups was not significant (P = 0.116). Moreover, the percent changes in cholesterol (P = 0.702), triglyceride (P = 0.080), low-density lipoprotein (LDL) (P = 0.986), high-density lipoprotein (HDL) (P = 0.687) and fasting blood glucose (P = 0.614) did not differ significantly between intervention and control groups. CONCLUSION: Although crocin supplements increased the serum cholesteryl ester transfer protein in patients with metabolic syndrome, this change was not significant between treatment and placebo groups. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520171002Septal hematoma due to stent implementation in the septal course of the left anterior descending artery25325610602ENRamin Khameneh-BagheriAssistant Professor, Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IranReza Jafarzadeh-EsfehaniPhD Candidate, Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad AND Researcher, Student Research Center, Sabzevar University of Medical Science, Sabzevar, IranMostafa AhmadiAssistant Professor, Department of Cardiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran0000-0001-7820-0297Journal Article20160809BACKGROUND: The interventricular septal hematoma (IVSH) is a rare and potentially lethal finding. There are variously reported etiologies including instrumental damages during cardiac interventions. Although there are not enough studies available, conservative management is considered as a preferable approach in stable patients.CASE REPORT: A 45-year man smoker with the previous history of percutaneous coronary intervention (PCI), admitted with unstable angina in present visit. Coronary angiography showed significant in-stent restenosis (ISR) of the left anterior descending (LAD) artery stent. During our intervention for treatment of the ISR, the wire movement caused a diffuse dissection without any runoff, in the distal portion of the LAD. Therefore two stents were deployed in the dissected segment with a short overlapping segment. Unfortunately, the overlapping segment of these stents was located in the myocardial bridge segment. Therefore the contraction of the interventricular septum (IVS) caused a scissor-like movement of the stents, and they ruptured the LAD into the septum. Therefore, the contrast agent was accumulated in the IVS. Immediately, a graft stent was deployed in the overlapping segment of stents and perforation became sealed. In echocardiography, the IVS diameter increased to 30 mm. Since the patient was hemodynamically and electrically stable, he underwent conservative approach and after two months the septum returned to the normal size.CONCLUSION: During PCI on the LAD artery, the implantation of stents in the septal course with a short overlapping segment can result in coronary perforation, and therefore IVS hematoma by the scissor effect. Septal hematoma may cause life-threatening arrhythmias or ventricular septal rupture, but if it is asymptomatic or uncomplicated. Conservative management is the best strategy. Cardiovascular research institute, Isfahan University of Medical SciencesARYA Atherosclerosis Journal1735-395513520170901Journal Index10594ENIndex Journal0000-0002-1825-0097Journal Article20180109Click to download the index of this issue.